MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)

Cerebral Adrenoleukodystrophy Clinical Trial

Official title:
MT2014-14 Intrathecal Administration of Mesenchymal Stem Cells (IT-MSC) for the Treatment of Advanced Cerebral Adrenoleukodystrophy (cALD)

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of mesenchymal stem cells (IT-MSC) in patients with active, advanced cerebral adrenoleukodystrophy (cALD).

Clinical Trial Description

This is a single-institution dose escalation study to determine the maximum tolerated dose (MTD) of intrathecally administered allogeneic, 3rd party mesenchymal stem cells (IT-MSC) in patients with active, advanced cerebral adrenoleukodystrophy (cALD). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02410239
Study type	Interventional
Source	Masonic Cancer Center, University of Minnesota
Contact
Status	Withdrawn
Phase	Phase 1
Start date	June 2015
Completion date	July 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04528706` - A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)	Phase 2
Recruiting	`NCT03789721` - Adrenoleukodystrophy National Registry Study
Terminated	`NCT03367546` - Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases	Phase 2
Recruiting	`NCT06030648` - MT2022-01: MSCs for ALD	Phase 1